Blueprint Medicines Acquires Lengo Therapeutics

Eli Lilly Acquires Engage Biologics

May 23, 2026

Biotechnology

Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

January 28, 2025

Healthcare Services

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Foundation Medicine Acquires Lexent Bio, Inc.

June 13, 2020

Biotechnology

Foundation Medicine has completed the acquisition of Lexent Bio, Inc., a California-based precision oncology company developing multiomics liquid biopsy platforms. The deal will accelerate Foundation Medicine's liquid biopsy research and development—incorporating low-pass WGS and methylation analysis into new assays—to expand diagnostic capabilities and support therapeutic development and earlier-stage patient monitoring.